20 May 2013Biotech

Ideas Matter: Philips and Microsoft in life sciences

At the Ideas Matter roundtable last week LSIPR spoke to Maaike van Velzen, general manager of Philips Group Innovation’s IP and Standards division, about the importance of using IP solutions to promote the company’s vision, and sharing IP with other companies in the creation of new products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

1 September 2026 Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product.

Biotech

Tempus AI bid to derail DNA patent case hits snag

31 August 2026 Efforts to shut down an eight-patent dispute over cancer-detection technology have run into a hurdle in a Delaware federal court.

Biotech

China-origin biotech assets and the hidden question of IP ownership

27 August 2026 As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler

More features

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Pinsents expands German patent practice with partner duo

Tempus AI bid to derail DNA patent case hits snag

Top law firms and individuals recognised in WIPR’s UK Patent Rankings 2026

Teva faces scrutiny over efforts to curb generic competition

FDA targets faster generic approvals in drive to slash drug prices

China-origin biotech assets and the hidden question of IP ownership

Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice

Ideas Matter: Philips and Microsoft in life sciences

More on this story

Editor's picks

Editor's picks

More features